<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616678</url>
  </required_header>
  <id_info>
    <org_study_id>VenTouch CT007</org_study_id>
    <nct_id>NCT03616678</nct_id>
  </id_info>
  <brief_title>VenTouch OUS Feasibility Study</brief_title>
  <official_title>Evaluation of The Minimally Invasive VenTouch™ System in The Treatment of Functional Mitral Valve Regurgitation (FMR): OUS Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mardil Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mardil Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate safety and efficacy of the&#xD;
      VenTouch System for treatment of subjects with functional MR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate safety and efficacy of the&#xD;
      VenTouch System for treatment of subjects with functional MR enrolling up to 15 subjects who&#xD;
      have been diagnosed with Grade 3-4 functional mitral valve regurgitation and deemed eligible&#xD;
      per assessment by the inclusion/exclusion criteria. The duration of the study follow-up is 36&#xD;
      months from the time of therapy adjustment. Data from this trial may be utilized in support&#xD;
      of a CE study in Europe and/or a pilot IDE study in the U.S. Follow-up testing will be&#xD;
      performed at 1, 3, 6, 12, 24, and 36 months post-therapy adjustment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate procedural feasibility through successful completion of implant and therapy adjustment procedures</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Evaluate procedural feasibility through successful completion of implant and therapy adjustment procedures and intraoperative transesophageal echocardiographic (TEE) evidence of MR severity reduction (a minimum of one grade)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate SAE Rates</measure>
    <time_frame>1 Month</time_frame>
    <description>Evaluate Serious Adverse Event (SAE) rates at 1 month post-therapy adjustment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate SAE Rates</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate Serious Adverse Event (SAE) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate MR Severity</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate MR severity reduction and mitral valve dimension reduction via echocardiographic core lab assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Reverse Ventricular Remodeling</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate reverse ventricular remodeling via echocardiographic core lab assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Symptoms by NYHA</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient symptoms as assessed by the NYHA functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Functional Status by Six-Minute Walk</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient functional status as assessed by Six-Minute Walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Functional Status by KCCQ</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient functional status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Functional Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>VenTouch System Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have &quot;moderately severe&quot; or &quot;severe&quot; mitral regurgitation (grade 3 or 4 MR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenTouch System</intervention_name>
    <description>The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.&#xD;
The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester.</description>
    <arm_group_label>VenTouch System Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥18 years of age&#xD;
&#xD;
          2. Symptomatic FMR of grade moderately severe to severe (3 to 4) due to either ischemic&#xD;
             or non-ischemic dilated cardiomyopathy with structurally normal leaflets determined by&#xD;
             echocardiography (preferably with echocardiographic evidence of EROA ≥ 0.20 cm2)&#xD;
&#xD;
          3. NYHA Class II to IV&#xD;
&#xD;
          4. Left Ventricular Ejection Fraction (LVEF) 20%-50% determined by echocardiography&#xD;
&#xD;
          5. Treatment and compliance with optimal guideline-directed medical therapy for heart&#xD;
             failure for at least 30 days&#xD;
&#xD;
          6. Subjects with a Class I indication for CRT implant according to current guidelines&#xD;
             should have CRT implant prior to entry into the study. Subjects who have existing CRT&#xD;
             implants may be included in the study if the implant has been in place for at least 90&#xD;
             days; reprogramming of an implanted CRT that results in increased biventricular pacing&#xD;
             (from &lt;92% to ≥92%) must be in place for at least 30 days.&#xD;
&#xD;
          7. Left Ventricular End Diastolic Diameter (LVEDD) of 55 to 80 mm as determined by&#xD;
             echocardiography&#xD;
&#xD;
          8. Indexed Left Ventricular End Diastolic Diameter (LVEDDi) of 30 to 40 mm/m2 (where&#xD;
             LVEDDi is calculated by LVEDD/Body Surface Area (BSA))&#xD;
&#xD;
          9. Subject is willing and available to return for study follow-up&#xD;
&#xD;
         10. Subject or legal representative understands and provides signed informed consent for&#xD;
             participation in study&#xD;
&#xD;
         11. Acceptance of subject for trial enrollment after review of all subject baseline data&#xD;
             by Study Selection Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy of less than 12 months due to conditions other than cardiac status&#xD;
&#xD;
          2. Anticipated need for LVAD or transplant within 12 months&#xD;
&#xD;
          3. Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy&#xD;
             or chronic outpatient oral steroid use&#xD;
&#xD;
          4. American College of Cardiology / American Heart Association (ACC/AHA) Stage D heart&#xD;
             failure&#xD;
&#xD;
          5. Six-minute walk distance &lt; 150 meters&#xD;
&#xD;
          6. Identified need for any cardiovascular surgery&#xD;
&#xD;
          7. STS score that suggests prohibitive surgical risk as determined by Subject Selection&#xD;
             Committee&#xD;
&#xD;
          8. Untreated clinically significant coronary artery disease&#xD;
&#xD;
          9. Any procedure, condition or cardiac anatomy that may impact or compromise the&#xD;
             pericardial space (e.g. prior mitral valve surgery, CABG, epicardial pacing leads,&#xD;
             pericarditis, or other procedure involving pericardial access)&#xD;
&#xD;
         10. Percutaneous coronary intervention, acute coronary syndrome (e.g. STEMI or non-STEMI&#xD;
             myocardial infarction, unstable angina) or clinically significant cardiac events (e.g.&#xD;
             hypotension, syncope, arrhythmias, embolism, heart failure exacerbation or any&#xD;
             hospitalization) within 30 days of enrollment&#xD;
&#xD;
         11. Thoracic or cardiac surgery contraindication (e.g., acute respiratory distress,&#xD;
             endocarditis, myocarditis, pericarditis)&#xD;
&#xD;
         12. Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured&#xD;
             or elongated chordae, prolapsed valve, perforated valve leaflets, significant&#xD;
             calcification in the annulus, or calcification in the leaflets that restricts motion)&#xD;
&#xD;
         13. Severe symptomatic carotid stenosis&#xD;
&#xD;
         14. Severe or sustained pulmonary hypertension, defined by resting pulmonary artery&#xD;
             systolic (PAS) pressure ≥70 mmHg determined by echocardiography or right heart&#xD;
             catheterization&#xD;
&#xD;
         15. Physical evidence of right-sided congestive heart failure with echocardiographic&#xD;
             evidence of moderate or severe right ventricular dysfunction or moderate to severe TR&#xD;
&#xD;
         16. Hypotension (systolic pressure &lt;90 mmHg)&#xD;
&#xD;
         17. Hemodynamic instability requiring inotropic support or mechanical heart assistance&#xD;
             within 30 days&#xD;
&#xD;
         18. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or any other structural heart&#xD;
             disease causing heart failure other than dilated cardiomyopathy&#xD;
&#xD;
         19. UNOS status 1 heart transplantation&#xD;
&#xD;
         20. Creatinine &gt; 2.5 mg/dL (221 µmol/L) and/or renal failure requiring dialysis&#xD;
&#xD;
         21. Stroke (cerebrovascular accident) or transient ischemic event (TIA) within 30 days of&#xD;
             enrollment&#xD;
&#xD;
         22. Active systemic infection or bleeding&#xD;
&#xD;
         23. Autoimmune disorders and/or the use of immune suppression therapy&#xD;
&#xD;
         24. Females who are pregnant (as documented by HCG beta pregnancy test in females of&#xD;
             child-bearing age) or lactating&#xD;
&#xD;
         25. Currently enrolled in another investigational drug or device study&#xD;
&#xD;
        Intra-Operative Exclusion Criteria:&#xD;
&#xD;
          1. Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured&#xD;
             or elongated chordae, prolapsed valve, perforated valve leaflets, significant&#xD;
             calcification in the annulus, or calcification in the leaflets that restricts motion)&#xD;
&#xD;
          2. Signs/indications of ischemia&#xD;
&#xD;
          3. Intra-operative coronary angiography demonstrates that there is compression of the&#xD;
             coronary arteries or reduction in coronary blood flow due to the VenTouch implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Hase, BS</last_name>
    <phone>763-710-4518</phone>
    <email>shase@mardil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Kent, MD</last_name>
      <phone>403-944-5480</phone>
      <email>william.kent@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>William Kent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherin Mok</last_name>
      <phone>604-806-8383</phone>
      <email>CMok@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Anson Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>35031</phone_ext>
      <email>Stephanie.Fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dave Nagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>4NU-470</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shakira Christie</last_name>
      <email>Shakira.Christie@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vivek Rao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon Vervais</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3783</phone_ext>
      <email>manon.vervais@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Anita Asgar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Bouchard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie De Québec (IUCPQ)</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Tremblay</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
      <email>hugo.tremblay@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>François Dagenais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux Heart University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orsolya Kemenes</last_name>
      <phone>+36 20 8250511</phone>
      <email>studycenter.sekk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Béla Merkely, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pacifica Salud Hospital Punta Pacifica</name>
      <address>
        <city>Panama City</city>
        <zip>0801</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margelis Muñoz</last_name>
      <phone>(507) 6499-9304</phone>
      <email>margelismunoz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christian Marin y Kall</last_name>
      <phone>305-799-1435</phone>
      <email>marinykallch@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel Ochoa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawia</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

